{"filings":[{"id":95303,"accession_number":"0001193125-26-210295","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29","event_type":"other_material","confidence":"high","bullets":["R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.","Cash, equivalents, and marketable securities $146.3M as of March 31; expects to fund ops into 2028 excluding $110M placement.","Budoprutug SC formulation showed robust B-cell depletion similar to IV; Phase 2 pMN trial granted FDA Fast Track Designation.","Initial budoprutug ITP data (low-dose B-cell and platelet) expected June 2026; pMN data Q4 2026.","CLYM116 nonhuman primate-to-human PK/PD modeling and initial safety data to be presented at ERA June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95302,"accession_number":"0001193125-26-205079","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Climb Bio reports positive SC formulation data; ITP data June 2026, pMN/SLE Q4 2026","event_type":"other_material","confidence":"high","bullets":["Topline Phase 1 SC data: robust B-cell depletion similar to IV; generally safe and well-tolerated.","Fast Track Designation received for primary membranous nephropathy (pMN).","Initial ITP Phase 1b/2a data from low-dose cohort expected June 2026.","Initial pMN Phase 2 and SLE Phase 1b data expected Q4 2026.","Budoprutug is an anti-CD19 mAb targeting B-cell mediated diseases; trials enrolling to plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95301,"accession_number":"0001193125-26-183711","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Climb Bio raises $110M in private placement of common stock and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$110M from 9.481M shares at $9.50 and 2.106M pre-funded warrants at $9.4999 each.","Closing expected April 29; participants include RA Capital, Adage Capital, Cormorant, and others.","Proceeds to fund late-stage development of budoprutug and CLYM116 for immune-mediated diseases.","Company to file resale registration statement within 45 days after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95300,"accession_number":"0001193125-26-142114","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Climb Bio SVP Finance to depart April 30; CFO adds principal accounting officer role","event_type":"leadership","confidence":"high","bullets":["Cindy Driscoll, SVP Finance and principal accounting officer, to separate from Climb Bio effective April 30, 2026, by mutual agreement.","CFO Susan Altschuller will also serve as principal accounting officer starting on the Separation Date.","Altschuller has been CFO since Oct 2025; prior CFO roles at Dragonfly Therapeutics, Cerevel Therapeutics, and ImmunoGen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108255,"accession_number":"0001193125-26-092520","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.","FY2025 R&D expense $46.7M vs $14.3M in FY2024; G&A expense $21.2M vs $16.0M.","Budoprutug SC formulation Phase 1 dosing completed; data expected H1 2026.","Budoprutug pMN, ITP, SLE trials ongoing; initial efficacy data expected H2 2026.","CLYM116 Phase 1 healthy volunteer study enrollment ongoing; initial data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108254,"accession_number":"0001193125-26-006994","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Climb Bio updates on budoprutug and CLYM116 trials; cash runway into 2028","event_type":"other_material","confidence":"high","bullets":["First patient dosed in PrisMN Phase 2 trial of budoprutug for primary membranous nephropathy (Nov 2025).","Received China IND clearance for budoprutug in SLE; parallel China Phase 1b to enroll lupus nephritis patients (Dec 2025).","Completed dosing of first cohort in Phase 1 trial of subcutaneous budoprutug and of CLYM116 in healthy volunteers (Dec 2025).","Expects initial data from SC budoprutug Phase 1 (H1 2026), budoprutug pMN Phase 2 (H2 2026), and CLYM116 Phase 1 (mid-2026).","Cash, cash equivalents, and marketable securities expected to fund operations into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124697,"accession_number":"0001193125-25-338318","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Climb Bio sues Alumis to avoid $3M milestone payment, disputes 'Product' definition under APA","event_type":"litigation","confidence":"high","bullets":["Filed complaint in Delaware Superior Court seeking declaratory judgment that budoprutug is not a 'Product' under the APA.","Alumis invoiced $3M milestone payment due Jan 1, 2026 for Phase 2 initiation; Climb denies any obligation.","Climb dosed first patient in Phase 2 trial on Nov 17, 2025; claims no Royalty-Bearing Patents exist to trigger milestone.","Dispute centers on interpretation of APA; Climb argues no patents transferred or filed within nine months of closing.","Climb states it attempted to resolve out of court but Alumis refused."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124696,"accession_number":"0001193125-25-315108","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Climb Bio exchanges 20.44M shares for pre-funded warrants; RA Capital voting capped at 33%","event_type":"other_material","confidence":"high","bullets":["Exchanged 20,440,000 shares for pre-funded warrants with $0.0001 exercise price via Section 3(a)(9) exemption.","Post-exchange shares outstanding: 47,744,435; RA Capital to own ~23% voting power.","RA Capital and affiliates agree to vote any holdings above 33% proportionally with other stockholders.","RA Capital may exchange additional shares for warrants with company's written consent.","Pre-funded warrants are exercisable immediately and include a 33% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124695,"accession_number":"0001193125-25-268075","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio Q3 2025 cash $175.8M; pipeline advances with budoprutug and CLYM116 trials","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $175.8M as of Sep 30, 2025; runway expected through 2027.","R&D expenses $9.1M (Q3 2025) vs $6.2M (Q3 2024); G&A $5.8M vs $5.5M.","Phase 2 PrisMN trial of budoprutug initiated; dosing expected in coming weeks.","CLYM116 Phase 1 trial cleared; first subject dosing expected by year-end 2025.","New leadership: CFO Susan Altschuller, SVP Tech Ops Adam Villa, SVP People Ashley Jones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124694,"accession_number":"0001193125-25-241951","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Climb Bio reports long-term Phase 1b data for budoprutug; up to 3-year proteinuria control","event_type":"other_material","confidence":"high","bullets":["Abstract published for budoprutug (anti-CD19 mAb) showing durable proteinuria control up to 3 years in four PMN patients.","Three of four patients required no further immunosuppressive treatment after up to 4 doses.","No treatment-related adverse events grade 3 or higher observed in the Phase 1b trial (NCT04652570).","Data support continued development of budoprutug for B-cell mediated diseases.","Company remains focused on advancing its pipeline; risks include clinical and regulatory uncertainties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124693,"accession_number":"0001193125-25-227025","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Climb Bio appoints Susan Altschuller as CFO, grants 600,000 stock options","event_type":"leadership","confidence":"high","bullets":["Appointed Susan Altschuller, Ph.D., MBA, as CFO and Treasurer effective Oct 1, 2025; previously CFO at Cerevel and ImmunoGen.","Base salary $510,000/year; eligible for annual bonus up to 40% of base.","Received option to purchase 600,000 shares under 2025 Inducement Plan; vesting 25% on one-year anniversary then monthly.","Board amended Inducement Plan to increase reserved shares from 1.25M to 2.0M.","Cindy Driscoll steps down as principal financial officer but continues as principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141385,"accession_number":"0001193125-25-221756","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Climb Bio reports CLYM116 preclinical data showing >70% IgA reduction and longer half-life vs sibeprenlimab","event_type":"other_material","confidence":"high","bullets":["In nonhuman primate study, CLYM116 showed ~2-3 times longer half-life and deeper IgA reduction vs sibeprenlimab at 6 mg/kg.","Subcutaneous CLYM116 demonstrated ~85% bioavailability and favorable tolerability in the NHP study.","CLYM116 Phase 1 trial in healthy volunteers expected to start Q4 2025 with initial data mid-2026.","CLYM116 is the only known 'sweeper' anti-APRIL monoclonal antibody in development for IgA nephropathy.","Updated KDIGO 2025 guideline highlights need for more active IgAN management, expanding potential market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141384,"accession_number":"0000950170-25-106913","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Climb Bio Q2 cash $187.4M, R&D $6.6M; budoprutug trials underway; new CMO","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $187.4M as of June 30, 2025; cash runway expected through 2027.","R&D expenses $6.6M in Q2 2025 vs $1.0M in Q2 2024; no acquired IPR&D expense in 2025.","Budoprutug ITP and SLE trials dosing patients; pMN Phase 2 to initiate; SC formulation Phase 1 data expected H1 2026.","CLYM116 investor event September 2025 with preclinical data; IND/CTA for IgAN expected H2 2025.","Edgar D. Charles, M.D., MSc appointed CMO, joining from Bristol Myers Squibb in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159203,"accession_number":"0001193125-25-142359","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Climb Bio appoints Cindy Driscoll as Principal Financial Officer; Emily Pimblett resigns","event_type":"leadership","confidence":"high","bullets":["Appointed Cindy Driscoll as SVP Finance, principal financial officer and principal accounting officer effective June 17, 2025.","Driscoll receives $355k base salary, 35% target bonus, and 200,000-share stock option under 2025 Inducement Plan.","Emily Pimblett resigns as SVP Finance and Chief Accounting Officer, effective June 30, 2025.","CEO Aoife Brennan ceases interim principal financial officer role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159202,"accession_number":"0001193125-25-135864","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Climb Bio shareholders elect two directors, ratify PwC as auditor for FY2025","event_type":"other","confidence":"high","bullets":["Judith Dunn, Ph.D. elected with 36,827,909 votes for, 6,615,228 withheld, 10,126,633 broker non-votes.","Stephen Thomas, Ph.D. elected with 41,359,959 for, 2,083,178 withheld, same broker non-votes.","Ratification of PricewaterhouseCoopers LLP as independent auditor: 53,442,396 for, 8,780 against, 118,594 abstentions.","Both directors will serve three-year terms expiring at 2028 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159201,"accession_number":"0001193125-25-125866","cik":1768446,"company_name":"Climb Bio, Inc.","ticker":"CLYM","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"COO Brett Kaplan departs Climb Bio; CEO Aoife Brennan named interim PFO","event_type":"leadership","confidence":"high","bullets":["Brett Kaplan, COO and principal financial officer, separated mutually on May 23, 2025.","Kaplan receives severance: 3 months base salary ($128,749.99) plus COBRA for 3 months.","CEO Aoife Brennan appointed interim principal financial officer, effective May 24, 2025, retaining CEO role.","No changes to Brennan's compensation or arrangements in connection with this appointment.","Kaplan reaffirms confidentiality, non-compete (amended to exclude CD19/APRIL drugs), and non-solicitation obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}